The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54% vs 66% (p = 0.107) and 90% vs 78% (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32%, 52%, and 21%, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.

Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma / Merli, F; Bertini, M; Luminari, Stefano; Mozzana, R; Botto, B; Liberati, Am; Baldini, L; Cabras, G; DI VITO, F; Orsucci, L; Naglieri, E; Polimeno, G; Marcheselli, Luigi; Pennese, E; Vitolo, U; Federico, Massimo; Gallo, E.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 48 (2):(2007), pp. 367-373. [10.1080/10428190601078100]

Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.

LUMINARI, Stefano;MARCHESELLI, Luigi;FEDERICO, Massimo;
2007

Abstract

The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54% vs 66% (p = 0.107) and 90% vs 78% (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32%, 52%, and 21%, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.
2007
48 (2)
367
373
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma / Merli, F; Bertini, M; Luminari, Stefano; Mozzana, R; Botto, B; Liberati, Am; Baldini, L; Cabras, G; DI VITO, F; Orsucci, L; Naglieri, E; Polimeno, G; Marcheselli, Luigi; Pennese, E; Vitolo, U; Federico, Massimo; Gallo, E.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 48 (2):(2007), pp. 367-373. [10.1080/10428190601078100]
Merli, F; Bertini, M; Luminari, Stefano; Mozzana, R; Botto, B; Liberati, Am; Baldini, L; Cabras, G; DI VITO, F; Orsucci, L; Naglieri, E; Polimeno, G; Marcheselli, Luigi; Pennese, E; Vitolo, U; Federico, Massimo; Gallo, E.
File in questo prodotto:
File Dimensione Formato  
Long term results.....pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 372.98 kB
Formato Adobe PDF
372.98 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/612177
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact